Kratom Supplier Qualification: What Responsible Brands Verify Before Accepting a Lot

August 30, 2026

Last reviewed: August 30, 2026. Educational content for adults 21+. This is not medical or legal advice. Kiody does not sell concentrated 7-OH products.

Suggested page: Learning Center → Lab Testing & Product Quality
Secondary phrases: kratom supplier audit, botanical supplier verification, kratom raw material testing, kratom COA verification
Suggested slug: /learn/kratom-supplier-qualification/
Suggested SEO title: Kratom Supplier Qualification: Audits, Testing and COA Checks | Kiody
Suggested meta description: Learn how a documented kratom supplier-qualification program reviews identity, specifications, COAs, testing, traceability, imports, changes and corrective actions.

Kiody position: Kiody is 21+ and does not sell concentrated 7-hydroxymitragynine (7-OH). This guide distinguishes ordinary botanical leaf from extracts, enhanced products, concentrated 7-OH and synthesized or semi-synthesized derivatives. It makes no medical claims.

The short answer

Supplier qualification is the documented process used to decide whether a supplier, facility and specific material are suitable for an intended use. A responsible review goes beyond asking for a certificate of analysis. It identifies who grew, processed, tested, exported, imported and released the material; defines written specifications; verifies botanical identity; examines contaminant and alkaloid data; tests whether the supplier’s COAs are reliable; and creates rules for approval, monitoring, change control, suspension and disqualification.

A supplier can have an attractive website, a recent audit certificate and a passing COA yet still be unsuitable for a particular product. The opposite is also possible: a small supplier may lack polished marketing but maintain strong lot traceability, appropriate controls and responsive corrective-action records. Qualification should follow evidence and risk rather than branding, price or familiarity.

No supplier-qualification program makes kratom FDA approved, proves that a product is risk-free or resolves every federal, state and local legal question. FDA currently states that kratom is not lawfully marketed in the United States as a drug product, dietary supplement or food additive in conventional food. FDA also maintains Import Alert 54-15 for dietary supplements and bulk dietary ingredients that are or contain Mitragyna speciosa. Those positions must be stated separately from voluntary quality practices or the dietary-supplement CGMP principles discussed below.[1][2]

Why supplier qualification matters

Testing is important, but a finished laboratory report is only one view of one submitted sample. It does not explain whether the sample represented the full lot, whether the declared supplier actually handled the material, whether lots were blended before testing, whether a processor changed drying conditions or whether a failed result was replaced by an unexplained retest.

Supplier qualification fills that gap. It connects the physical material to the organizations and records behind it.

A useful program asks five basic questions:

Who is responsible? Identify the grower, collector, processor, broker, exporter, importer, contract manufacturer and laboratory rather than treating “the supplier” as one vague entity.
What exactly is being supplied? Whole leaf, milled powder, pure-leaf capsules, extract and concentrated or enhanced products are not interchangeable.
What requirements must the material meet? Written specifications should cover identity, composition, purity and relevant contamination limits, plus destination-specific legal requirements.
What evidence supports each decision? COAs, audit reports, methods, representative samples, traceability records, complaints and corrective actions should connect to the same supplier, facility, material and lot.
What happens when something changes? A new facility, dryer, solvent, laboratory, farm region, capsule shell or alkaloid profile can invalidate an earlier approval.

Qualification is not a one-time badge. It is a controlled status that can be narrowed, suspended or withdrawn.

A necessary federal regulatory distinction

This article uses portions of 21 CFR Part 111 and FDA’s foreign-supplier-verification framework to explain established quality-system concepts. That does not mean FDA accepts kratom as a lawful dietary supplement.

FDA’s current kratom page says the agency considers kratom an inadequately supported new dietary ingredient and states that products containing it are not lawfully marketed as dietary supplements. FDA also states that adding kratom to conventional food creates an unsafe food-additive issue. A quality program cannot convert an unlawfully marketed article into a lawful one.[1]

Why discuss Part 111 at all? Because its requirements illustrate useful, concrete distinctions among specifications, identity testing, supplier COA reliance, representative sampling, quality-control review and records. For example, 21 CFR §111.75 says that reliance on a supplier’s COA for certain component specifications requires the manufacturer to first establish the COA’s reliability through confirmation, ensure that the COA states methods, limits and actual results, document how the supplier was qualified, and periodically reconfirm reliability. It separately requires at least one appropriate identity test or examination for each dietary ingredient unless a specific regulatory exemption applies.[3]

Those are valuable quality principles. They are not an FDA endorsement of kratom, Kiody or any supplier.

Start by defining the product form

A qualification decision should state exactly which form is covered. “Approved kratom supplier” is too broad.

Whole or crushed botanical leaf

Whole and crushed leaf preserve visible botanical features that may support macroscopic examination. The program should still address species identity, foreign matter, drying, storage, moisture exposure, microbial contamination, pesticides, heavy metals, origin and lot segregation.

Milled botanical leaf powder

Grinding reduces visible identifying features and increases surface area. Powder may be more vulnerable to mixing, cross-contact, moisture uptake and sampling error. Microscopy, DNA methods and chemical fingerprinting may be useful parts of a fit-for-purpose identity strategy, but no single technique answers every quality question.

Pure-leaf capsules

Pure-leaf capsules should be qualified as both leaf powder and a finished dosage form. The review should cover the powder source, capsule-shell material, approximate fill weight, fill uniformity, encapsulation facility, lot code and any processing aid. Kiody describes its current capsules as approximately 500 mg of pure leaf powder per capsule; that description should be confirmed by batch records and weight checks rather than assumed from capsule size.

Botanical extract

An extract requires a separate approval because extraction changes the matrix and concentration. The supplier record should identify the source leaf, extraction solvent, ratio or standardization claim, concentration process, carriers, residual-solvent controls and quantitative alkaloid method. Approval of a powder supplier does not automatically approve that supplier’s extract.

Enhanced or fortified product

Enhanced products combine leaf or extract with added alkaloid-rich material. They require specific composition, manufacturing-pathway and legal review. A familiar botanical name does not make a fortified product equivalent to ordinary leaf.

Concentrated 7-OH and synthesized or semi-synthesized derivatives

These products should be treated as a distinct high-risk category, not as a stronger “strain.” Kiody does not sell concentrated 7-OH. Mitragynine pseudoindoxyl, MGM-15 and MGM-16 entered federal Schedule I on August 26, 2026. The separate federal proposal for 7-OH above a specified threshold was still pending as of this draft date, with comments extended through September 10, 2026.[11][12][13]

Map the real supply chain

A broker’s invoice is not a supply-chain map. Before approval, create a role map that identifies:

the botanical grower or collection network, when available;
the first consolidator;
the washing, drying or fermentation location;
the milling and sieving facility;
any sterilization or microbial-reduction facility;
the extractor, if applicable;
the encapsulator or finished-product manufacturer;
the warehouse and fulfillment location;
the exporter of record;
the U.S. importer or FSVP importer, when applicable;
the contract laboratories;
the person authorized to investigate complaints and deviations; and
the legal entity that signs specifications and supply agreements.

The purpose is not to publish confidential supplier information. It is to make sure the quality team knows which entity performed each material step.

If a seller will not identify the actual processing facility, the buyer cannot meaningfully evaluate that facility’s controls. “Made for,” “distributed by” and “tested by” are different statements. None proves who manufactured the lot.

Build written specifications before reviewing a COA

A COA cannot pass or fail a material unless the buyer knows the specification. The specification should be established before results arrive, not adjusted after an inconvenient number appears.

A material specification may include:

accepted botanical name and plant part;
permitted physical form;
identity test or examination;
organoleptic and foreign-matter criteria;
moisture content or water activity, with the method and test temperature where relevant;
microbiological criteria;
elemental-impurity or heavy-metal criteria;
pesticide analyte list and decision rules;
mycotoxin criteria when supported by the hazard assessment;
residual-solvent criteria for extracts;
mitragynine and 7-OH reporting requirements;
screening for mitragynine pseudoindoxyl, MGM-15 and MGM-16 when appropriate;
prohibited added or synthetic substances;
ingredient and capsule-shell requirements;
packaging and seal requirements;
label, lot-code and traceability fields;
sample-retention requirements;
destination-specific product thresholds; and
change-notification requirements.

The analyte list should match the material and risk. A leaf-powder panel and a liquid-extract panel may require different preparation, detection limits and acceptance criteria. A generic “full panel” is not a technical specification.

21 CFR §111.70 illustrates the importance of establishing identity, purity, strength, composition and contamination specifications. Section 111.75 then addresses how conformity is determined. Again, these provisions do not resolve FDA’s position on kratom marketing; they provide a useful structure for thinking about evidence.[3][4]

What a supplier COA should contain

A COA should be lot-specific and understandable without relying on a sales representative’s oral explanation. Useful fields include:

supplier and manufacturing-facility identity;
material name and unambiguous product form;
supplier lot and manufacturer lot, if different;
date manufactured, received and sampled;
sample identifier;
laboratory name and address;
date received, tested and reported;
test or examination method;
unit of measure;
specification or acceptance limit;
actual result, rather than “pass” alone;
reporting limit, LOD or LOQ when relevant;
sample preparation or matrix designation;
authorized review signature or electronic approval;
report version and amendment history; and
an explanation for subcontracted tests.

The buyer should be able to match the COA to the package and receiving record. A PDF filename or QR code is not enough if the lot identifier on the document does not match the physical product.

How to establish that a supplier’s COA is reliable

“We trust this supplier” is not a confirmation study. Reliability should be demonstrated with planned comparisons.

Step 1: Choose the specifications being confirmed

Identity, microbiology, heavy metals, pesticides and alkaloids present different risks and method considerations. Define which supplier results will be independently checked and why.

Step 2: Use a representative, sealed sample

If the supplier sends a special qualification sample that is not drawn from a commercial lot, the comparison may say little about routine performance. Record who selected the units, how increments were taken, whether a composite was made, how the sample was sealed and whether both laboratories received equivalent material.

Step 3: Use a capable independent laboratory

Review scope, method suitability, matrix, calibration, reporting limits and subcontracting. Accreditation is useful evidence of a quality system, but it is not proof that every method is suitable for every kratom matrix.

Step 4: Define comparison rules before seeing results

Two laboratories will not always report identical numbers. The protocol should state how qualitative results, counts, recoveries, near-limit findings and quantitative alkaloid differences will be evaluated. A reasonable comparison considers analytical uncertainty and sample heterogeneity; it does not erase unexplained differences.

Step 5: Investigate discrepancies

Possible causes include nonrepresentative sampling, different sample preparation, method selectivity, reporting-limit differences, unit-conversion mistakes, data transcription, material instability or a supplier result that is not truly lot-specific.

Step 6: Document approval and reconfirmation

The record should state which COA fields may be relied on, which still require buyer testing, how often reliability will be reconfirmed and what events trigger an early review.

Part 111 specifically calls for periodic reconfirmation when a manufacturer relies on a qualified supplier’s COA for covered component specifications. A supplier’s good history can justify a risk-based frequency; it does not justify eliminating oversight.[3]

Identity deserves its own decision

Botanical identity is not the same as alkaloid potency. A mitragynine result may support chemical consistency, but it does not automatically exclude substitution, mixing or another plant material.

An identity strategy may combine:

label and chain-of-custody review;
organoleptic examination;
macroscopic examination for whole or crushed leaf;
microscopy for powdered material;
DNA-based methods, with attention to processing and reference sequences; and
chemical fingerprinting using a qualified method and appropriate reference materials.

The method must fit the form. Aggressive extraction or heat may affect DNA quality. Milling removes macroscopic features. A narrow targeted chemical assay may miss an unexpected substitute. Multiple complementary tools can provide stronger evidence than a single disconnected result.

For a deeper treatment, link to Kiody’s botanical identity guide and method-validation guide.

Review the laboratory, not just its logo

Supplier qualification should identify who generated each result. Questions include:

Is the lab independent, supplier-owned or a subcontractor?
Is the relevant method included in the laboratory’s accredited scope, if accreditation is claimed?
Was the method validated or verified for this matrix?
Are calibration standards traceable and within expiration?
Does the method distinguish mitragynine, 7-OH and relevant derivatives?
Are recovery, precision, blanks and continuing-calibration checks acceptable?
Are presumptive microbiology findings confirmed?
Are LOD and LOQ low enough for the specification and legal threshold?
How are amended reports controlled?
Does the lab participate in relevant proficiency testing or interlaboratory comparisons?

A laboratory’s name on a COA is evidence of authorship. It is not a substitute for method review.

Evaluate hazards by material and process

Supplier qualification should be driven by known and reasonably foreseeable hazards, not a recycled checklist.

Microbiological hazards

Botanical powders may require attention to Salmonella, pathogenic E. coli and process-hygiene indicators. A negative result applies to the tested sample under the stated method and sampling plan; it does not prove every gram in a lot is pathogen-free.

Review drying, water exposure, storage, pest control, employee hygiene, sanitation and any validated microbial-reduction step. Ask whether treated and untreated material can be confused or recontaminated afterward.

Elemental impurities

Lead, arsenic, cadmium and mercury may reflect soil, water, processing equipment or environmental exposure. Review units, sample mass, digestion and instrumentation. Total arsenic and inorganic arsenic are not interchangeable results.

Pesticides

There is no honest one-number “pesticide-free” claim based on a limited screen. Review the actual analyte list, methods and reporting limits. EPA tolerances are pesticide- and commodity-specific; do not invent a universal kratom pesticide limit.

Mycotoxins

Where the hazard assessment supports testing, identify the compounds, matrix, method and limits. A yeast-and-mold count does not measure aflatoxins or other mycotoxins.

Residual solvents

This issue is primarily relevant to extracts or materials exposed to processing solvents. A powder supplier’s approval does not qualify an extract made by a different process. Review the solvent list, extraction records, headspace-GC method and units.

Foreign material and physical hazards

Evaluate screens, sieves, magnets, metal detection, glass-and-brittle-plastic controls, receiving inspections and complaint history. “Natural” does not mean free from stones, fibers, metal or packaging fragments.

Alkaloid composition and prohibited substances

Require quantitative, lot-specific reporting suited to the destination. State laws use different denominators and product rules. Two percent of total alkaloids is not two percent of product weight. Georgia uses simultaneous per-gram and per-serving limits, Florida uses concentration and ratio tests, Utah limits its pure-leaf category to 0.4% 7-OH of total kratom alkaloids, and other jurisdictions take different approaches or prohibit all kratom.

A nationwide seller therefore needs both a product specification and a destination rule set. Supplier approval does not make every approved lot eligible for every destination.

Audits: useful, but only when scoped correctly

An audit is a structured review against defined criteria. It may be remote, document-based or onsite. The audit report should identify:

the legal entity and physical facility audited;
the address and operations within scope;
the audit date and auditor qualifications;
the standard or checklist used;
whether the audit was announced;
products and processes sampled;
observations and objective evidence;
nonconformities and their severity;
corrective actions and evidence of completion; and
report restrictions or conflicts of interest.

A certificate without the underlying scope may cover warehousing while the buyer assumes it covers milling and extraction. An audit of headquarters does not necessarily cover the contract facility that processed the lot. A passing audit is time-limited evidence, not immunity from future failures.

Onsite review is particularly valuable when a hazard is controlled by a process that cannot be fully evaluated from finished testing—for example, a microbial-reduction step, segregation of synthetic compounds, or sanitation after allergen-containing production.

Foreign suppliers and import controls

Foreign Supplier Verification Programs under 21 CFR Part 1, Subpart L use a risk-based structure that includes hazard analysis, supplier-performance evaluation, approval, verification activities, corrective action and records. Section 1.506 lists onsite audits, sampling and testing, and review of relevant food-safety records among appropriate verification activities. Section 1.505 calls for evaluation of food risk and supplier performance, with reevaluation at least every three years or sooner when new information arises under the standard framework.[5][6][7]

Dietary supplements and components can be subject to modified FSVP provisions under §1.511, depending on the importer’s role and compliance with applicable Part 111 specifications and verification requirements. Applicability is fact-specific and should be reviewed by qualified counsel or an FSVP professional.[8]

For kratom, an additional issue is decisive: FDA’s Import Alert 54-15 directs detention without physical examination of dietary supplements and bulk dietary ingredients that are or contain Mitragyna speciosa. The alert was listed as updated August 17, 2026 when this draft was prepared.[2]

A clean audit or passing COA does not cancel an import alert, guarantee admission or establish lawful marketing. Do not advise a supplier to disguise, misdeclare or relabel kratom as tea, incense, potpourri or another commodity. Accurate identity and entry information are fundamental.

A practical supplier-risk model

Kiody could use four internal risk tiers. These are proposed quality categories, not legal classifications.

Tier 1: Lower-complexity botanical leaf

Example: identifiable whole or powdered leaf from a fully mapped processor with stable history, acceptable independent confirmation and no material changes.

Possible controls:

approved facility and material specification;
independent identity testing;
risk-based contaminant and alkaloid confirmation;
annual record review;
periodic audit or justified alternative; and
immediate change notification.

Tier 2: New, changed or weak-history leaf supplier

Example: a new mill, new growing region, incomplete complaint history or repeated COA amendments.

Possible controls:

enhanced document review;
testing of multiple consecutive commercial lots;
direct sampling controls;
onsite or live remote audit;
shorter approval term; and
no reduced testing until performance is demonstrated.

Tier 3: Extract or complex finished product

Example: water or ethanol extract, liquid shot, flavored product or multi-ingredient capsule.

Possible controls:

separate material and process specifications;
source-leaf traceability;
solvent and carrier review;
matrix-specific alkaloid method;
residual-solvent testing where relevant;
formulation and label reconciliation;
stability or shelf-life support; and
destination-specific legal review.

Tier 4: Ineligible or prohibited category

Example: concentrated 7-OH, intentionally added mitragynine pseudoindoxyl, MGM-15, MGM-16, undisclosed synthetic or semi-synthetic material, or a supplier unwilling to identify the manufacturing pathway.

Kiody does not sell concentrated 7-OH. Products in this tier should not proceed through ordinary supplier approval or commerce review.

A 12-stage qualification workflow

1. Define the intended material

Record plant, plant part, form, intended use, package, target markets and prohibited features.

2. Screen legal and regulatory status

Review federal, state and local restrictions, import status and destination rules. Legal review comes before commercial enthusiasm.

3. Identify every critical entity

Map grower, processor, broker, exporter, importer, manufacturer, warehouse and laboratories.

4. Issue a focused questionnaire

Ask only questions that can be supported with records. A yes/no answer should point to a procedure, log, report or responsible person.

5. Establish specifications

Approve written identity, composition, contaminant, packaging and documentation requirements before evaluating routine lots.

6. Review documents

Examine facility registrations where applicable, licenses, audit scope, organization chart, process flow, food-safety or quality plans, sanitation, pest control, calibration, training, complaint and recall procedures.

7. Audit based on risk

Choose onsite, remote or records-based verification and document why the depth and frequency are appropriate.

8. Qualify samples and methods

Use commercial lots, a documented sampling plan and laboratories capable of the matrix and specification.

9. Compare supplier and independent results

Apply preapproved decision rules. Investigate differences rather than selecting the more favorable number.

10. Approve with a defined scope

State approved facility, material, form, specification, testing plan, expiration or review date and any restrictions.

11. Monitor performance

Track incoming-lot results, deviations, complaints, rejected lots, late documents, amended COAs, audit findings and responsiveness.

12. Reevaluate and change status

Reapprove, condition, suspend or disqualify based on evidence. Do not leave a supplier “approved” indefinitely because no one updated the file.

Events that should trigger early reevaluation

Do not wait for an annual review when any of these occurs:

facility or ownership change;
new farm region or consolidator;
material change in drying, milling, microbial reduction or extraction;
new contract laboratory or test method;
new capsule shell, carrier or processing aid;
unexplained shift in mitragynine, 7-OH or fingerprint profile;
pathogen, heavy-metal, pesticide or prohibited-substance failure;
major audit nonconformity;
repeated COA amendments;
consumer complaint trend;
recall, warning letter, import detention or enforcement action;
failure to notify the buyer before a change;
loss or narrowing of a laboratory accreditation scope;
inability to trace a lot; or
change in federal, state or local law.

Corrective action and supplier status

An investigation should separate the immediate correction from the corrective action.

Removing one mislabeled pallet is a correction. Determining why the wrong label was issued, changing label controls, retraining personnel and verifying effectiveness are corrective actions.

Possible supplier statuses include:

prospective: information gathering only;
conditionally approved: limited lots or enhanced testing;
approved: authorized for the listed scope;
on watch: increased monitoring while a concern is evaluated;
suspended: no new receipt or use pending resolution;
disqualified: not eligible for purchase; and
inactive: no current business, with requalification required before reuse.

Status decisions should identify who approved them and when. Sales urgency should not override a quality hold.

Ten documents that look stronger than they are

A generic COA: It may not match the delivered lot.
A “GMP certified” logo: The certifier, standard, scope, facility and date may be unclear.
A laboratory accreditation certificate: It may not cover the relevant method.
An organic certificate: It does not replace identity, pathogen, heavy-metal or alkaloid review.
A certificate of origin: It may identify the exporting country, not the growing region or processing facility.
A statement that a product is “FDA registered”: Facility registration is not product approval.
A sterilization certificate: It does not prove post-treatment protection or lot identity.
A one-page audit certificate: It may omit serious observations and corrective actions.
A nondisclosure agreement: It protects information; it does not excuse withholding essential quality evidence.
A long relationship: History is useful data, but it does not replace current verification.

Five worked qualification scenarios

Scenario 1: A polished supplier with copied COAs

A supplier submits professional-looking COAs for three lots. The result values, dates and sample identifiers are identical.

Response: Place qualification on hold. Ask the issuing laboratory to confirm authenticity through an authorized channel, obtain chain-of-custody records and independently test sealed commercial-lot samples. Identical reports may reflect templating, reused data or a legitimate document-control issue; they require investigation, not accusation or automatic acceptance.

Scenario 2: A leaf supplier adds steam treatment

An approved powder supplier installs a microbial-reduction process and says the change only improves safety.

Response: Treat it as a controlled change. Review validation, equipment, operating limits, post-treatment handling, identity and alkaloid comparability, packaging, residual moisture and lot coding. Beneficial intent does not remove the need to assess unintended effects or recontamination.

Scenario 3: An extract is offered under an approved powder account

The same sales contact offers a “10×” extract and refers to the existing supplier approval.

Response: Open a new material qualification. Define what 10× means, identify the extractor, source leaf, solvent, yield, carrier and alkaloid profile, and establish matrix-specific specifications. Powder approval does not transfer.

Scenario 4: A near-threshold 7-OH result

A lot’s 7-OH result is close to a destination’s numerical limit, and the supplier COA reports fewer decimal places than the independent laboratory.

Response: Do not round casually or average the two results. Confirm units and denominator, review LOQ and uncertainty, apply the predetermined decision rule and consider destination exclusion. Legal eligibility is not established by choosing the lower number.

Scenario 5: A foreign supplier passes testing but appears on an import alert

Independent tests meet the buyer’s specification.

Response: Keep quality evidence separate from admissibility and marketing status. FDA Import Alert 54-15 and FDA’s current kratom position remain applicable. A passing test does not guarantee entry or lawful sale. Escalate to qualified customs and regulatory counsel; do not misdescribe the shipment.

Proposed 30-field Kiody supplier-qualification record

Supplier legal name
Supplier role
Physical facility address
Ownership and key quality contact
Material and product form
Botanical name and plant part
Internal material code
Intended use
Approved destination limitations
Supply-chain role map
Growing or collection region
Process-flow version
Critical process controls
Specification number and version
Identity method
Contaminant panel and rationale
Alkaloid panel, units and denominator
Prohibited-substance review
Supplier laboratory or laboratories
Independent laboratory
COA-authenticity confirmation
COA-reliability comparison results
Sampling-plan reference
Audit date, type and scope
Open nonconformities
Complaint, rejection and recall history
Import and regulatory-status review
Change-notification agreement
Approval status, scope, owner and date
Reconfirmation date and trigger events

This record is a proposed Kiody quality tool, not a government form. The underlying evidence should remain linked and version controlled.

Questions a consumer or retailer can reasonably ask

A business may protect confidential supplier identities, but it should still be able to answer practical quality questions:

Is the COA for the exact lot being sold?
Who collected the sample?
Does the package lot match the report?
Was botanical identity evaluated separately from alkaloid potency?
Which contaminants were tested, by which methods and at what reporting limits?
Are actual numerical results available?
Is the product pure leaf, an extract or enhanced?
Does the alkaloid report state units and denominator?
How are complaints and recalls handled?
What happens when a supplier changes a facility or process?

Transparency does not require publishing trade secrets. It does require enough information to avoid misleading a buyer about what was tested and what the result means.

Frequently asked questions

1. What is kratom supplier qualification?

It is a documented decision process for approving a particular supplier, facility and material for a defined use. It includes specifications, evidence review, testing, audit or other verification, monitoring and change control.

2. Is a supplier questionnaire enough?

No. A questionnaire collects representations. Important answers should be supported by procedures, records, reports, interviews, audit evidence or independent testing.

3. Does a COA qualify a supplier?

No. A COA is one record for one sample or lot. Qualification also evaluates facility controls, methods, traceability, history and the reliability of routine COAs.

4. Can a buyer rely on a supplier COA?

Reliance should be specification-specific and supported by confirmation. Part 111’s COA framework requires initial qualification, method and result information, documentation and periodic reconfirmation for covered specifications. Identity has separate testing requirements.[3]

5. Does “GMP certified” mean FDA approved?

No. FDA does not approve a product because a private organization issued an audit certificate. Review the certifier, standard, facility, scope, findings and date.

6. Is an ISO/IEC 17025 laboratory automatically suitable?

No. Accreditation can support confidence in a laboratory’s quality system, but the relevant analyte, method and matrix should be within scope and technically fit for the decision.

7. Must every lot be retested?

The appropriate testing plan depends on the specification, risk, law, supplier history and applicable requirements. Reduced testing should be justified and documented, not assumed. Identity, legal thresholds and high-severity hazards may require different approaches.

8. Why is a sampling plan part of supplier qualification?

Because a precise laboratory method cannot correct a sample that does not represent the lot. Sampling responsibilities, locations, increments, composites, seals and custody should be defined.

9. Does approval cover every product from a supplier?

No. Approval should be limited to named facilities, materials, forms and specifications. Powder, capsules, extracts and mixed products need distinct review.

10. What is the difference between an audit and testing?

Testing examines a sample for selected characteristics. An audit examines systems, processes and records. They answer different questions and can complement each other.

11. Can an approved supplier make changes without notice?

A quality agreement should require advance notice for changes that may affect identity, composition, hazards, methods, facilities, ingredients or legal eligibility. Significant unapproved change can trigger suspension.

12. Does supplier qualification prove a kratom product is legal?

No. Product legality depends on federal, state and local law, product form, composition, labeling, age rules, destination and sometimes registrations or permits. FDA’s federal marketing position remains separate from quality documentation.[1]

13. Does a passing COA override FDA Import Alert 54-15?

No. A passing COA may be quality evidence, but it does not guarantee admissibility or cancel an import alert.[2]

14. How should 7-OH be reviewed?

Use a qualified quantitative method, lot-specific result, correct units and the denominator required by the destination. Distinguish naturally occurring trace content in leaf from concentrated, enhanced, synthesized or semi-synthesized products.

15. Are mitragynine pseudoindoxyl, MGM-15 and MGM-16 ordinary kratom alkaloids for supplier purposes?

They should not be treated as ordinary leaf specifications. All three entered federal Schedule I on August 26, 2026. DOJ announced limited enforcement discretion only for incidental trace mitragynine pseudoindoxyl in a product otherwise consistent with botanical kratom; it created no legal exemption or numerical safe harbor and does not cover MGM-15, MGM-16 or deliberately manufactured or added MP.[12][13]

16. Does Kiody sell concentrated 7-OH?

No. Kiody is 21+ and does not sell concentrated 7-OH.

Current federal 7-OH note — August 30, 2026

Two federal actions must not be blended together.

First, DEA’s proposed temporary scheduling of 7-OH above a specified threshold was not yet an effective scheduling order as of this draft. The proposal describes a 0.050% dry-weight threshold and an alternative article trigger involving more than 1 mg of 7-OH, subject to the proposal’s exact definitions. HHS extended the public-comment deadline through September 10, 2026.[11][14]

Second, DEA’s separate temporary order placing mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I became effective August 26, 2026. DOJ’s trace-MP enforcement-discretion statement does not change MP’s Schedule I status, create a safe harbor, extend to MGM-15 or MGM-16, or protect intentionally added, fortified, concentrated or manufactured MP.[12][13]

Supplier questionnaires, specifications and prohibited-substance agreements should reflect this distinction. A supplier’s statement that a product is “botanical” is not enough; the manufacturing pathway and analytical evidence matter.